Half of the planned 200 ALS patients have joined Medicinova’s expanded access program evaluating the experimental drug MN-166.

Neurizon hopes to initiate its regimen of the HEALEY-ALS trial in Q4 2025. Image credit: MAXIMUM ART / Shutterstock.com The US Food and Drug Administration (FDA) has released its clinical hold on ...

A new treatment for amyotrophic lateral sclerosis, or ALS, has been approved by the US Food and Drug Administration. The FDA announced approval of Relyvrio, developed by Amylyx Pharmaceuticals, on ...

At 71 years old, facing a terminal diagnosis, Colorado resident Tom Pringle has one more thing he wants to do before he dies: help other people in similar situations by trying an experimental drug to ...

A recently approved amyotrophic lateral sclerosis treatment will be $158,000 for a year’s supply, the product’s manufacturer said in a Sept. 30 investor conference call, according to The New York ...

Eight years after receiving a life-shattering diagnosis, a New Jersey mother credits an “amazing” new drug for stopping her disease in its tracks. Raziel Green, 52, an active runner and mother of two, ...

Scientists have learned more about the effects of an experimental amyotrophic lateral sclerosis (ALS) drug candidate that failed its promise. This study has shown that the drug was able to enter the ...

Rickey Malloy (left), who receives tofersen treatment for SOD1-ALS at WashU Medicine, plays a round of golf with his wife, Jenny, and their son, Kash. Long-term use of tofersen, a new drug approved by ...

The amyotrophic lateral sclerosis market is expected to grow owing to the increasing prevalence of the disease, along with the promising emerging pipeline therapies, such as Masitinib (AB Sciences), ...

A new drug may slow progression of — and even reverse — symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...